N/A
Completed N=728
A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)
Source: ClinicalTrials.gov NCT00705289 ↗Enrolled (actual)
728
Serious AEs
5.6%
Results posted
Jun 2010
Primary outcomePrimary: Baseline Raw Disease Activity Score for 28 Joint Swollen and Tender Joint Count (DAS28) by Age — 5.2 Score on a scale — p=0.0003
Summary
This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics. Patients in this study will be treated for RA with infliximab and in a usual manner as decided by their physician.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Baseline Raw Disease Activity Score for 28 Joint Swollen and Tender Joint Count (DAS28) by Age |
5.2 | 0.0003 sig |
| PRIMARY Baseline Raw DAS28 by Time Since Diagnosis |
5.2 | 0.7991 |
| PRIMARY Baseline Raw DAS28 by Gender |
5.2; 5.23; 5.19 | 0.7152 |
| PRIMARY Baseline Raw DAS28 by Country of Residence |
5.38; 5.43; 4.57; 4.97; 5.38; 5.15 | <0.0001 sig |
| PRIMARY Baseline Raw DAS28 by Previous Anti-Tumor Necrosis Factor (Anti-TNF) Therapy |
5.2; 5.3; 5.2; 5.3 | — |
Eligibility Criteria
Inclusion Criteria
- Subject has been diagnosed with RA
- Physician has decided, with the subject's consent, to begin treatment with infliximab
- Written informed consent form signed by both the subject and the physician.
Exclusion Criteria
- Subjects who have previously been exposed to infliximab
Data sourced from ClinicalTrials.gov (NCT00705289). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.